A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals
Examining the Efficacy of a Soft Soy Pretzel Intervention in Altering Chronic Inflammation and Immune Profiles in Obese Individuals
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVES:
I. Assess alterations in chronic inflammatory markers with soft soy pretzel (SSP) intervention among individuals with obesity.
II. Define immune cell populations in obese individuals with SSP intervention.
OUTLINE: Patients with a body mass index (BMI) ≥ 30 and C-reactive protein (CRP) ≥ 0.06 mg/dL are randomized to 1 of 2 arms. Patients with BMI 18.5-24.9 and detectable CRP are assigned to arm III.
ARM I: Patients consume 8 SSP bites twice daily (BID) for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume wheat pretzel (WP) bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.
ARM II: Patients consume 8 WP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume SSP bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.
ARM III: Assigned to Arm I.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures, lifestyle considerations, and availability for the duration of the study
- Males sex
- 18 and 49 years of age
Height and weight or calculated BMI for:
- Obese participants must be ≥ 30 kg/m^2
- Non-obese (healthy) participants must be between 18.5 and 24.9 kg/m^2
Exclusion Criteria:
- Inability to comply with all study procedures, lifestyle considerations, and availability for the duration of the study
- Known allergy or intolerance to soy, wheat, or any other ingredients in study intervention
- Current or prior history of type 2 diabetes mellitus as defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) E11
- Current or prior history of cancer (excluding non-melanoma skin cancers)
- History of blood clotting disorders or adverse events relating to blood draws
- Use of antibiotic regime lasting longer than one week within the last six months
- Current enrollment in other research studies for weight loss
- Actively trying to lose weight and/or use of medications for weight loss within the last three months
- Strict veganism (no consumption of animal, fish, or egg products)
- Heavy alcohol consumption (defined as consumption of > 14 drinks/week on average)
- Current or prior history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias
- Regular usage of inflammation lowering medications which include but not limited to nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, and naproxen, or anti-pyretic medications such as acetaminophen
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (SSP, WP)
Patients consume 8 SSP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28).
Following the washout period, patients consume WP bites BID for 14 days (days 28-42).
Patients also undergo collection of blood and urine samples on study.
|
補助研究
血液と尿のサンプルを採取します
他の名前:
Consume SSPs
他の名前:
Consume WPs
他の名前:
|
|
実験的:Arm II (WP, SSP)
Patients consume 8 WP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28).
Following the washout period, patients consume SSP bites BID for 14 days (days 28-42).
Patients also undergo collection of blood and urine samples on study.
|
補助研究
血液と尿のサンプルを採取します
他の名前:
Consume SSPs
他の名前:
Consume WPs
他の名前:
|
|
実験的:Arm III (WP, SSP)
Patients receive intervention as in Arm I. Patients also undergo collection of blood and urine samples on study.
|
補助研究
血液と尿のサンプルを採取します
他の名前:
Consume SSPs
他の名前:
Consume WPs
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Differences in chronic inflammatory biomarkers
時間枠:Up to 42 days
|
Will be compared between interventions using a repeated measures analysis of variance and between obese and normal body mass index groups.
Inflammatory biomarker concentrations will be determined by comparing signal intensity of each well to a generated standard curve and averaged to make a single data point per biomarker per individual.
Biomarker concentrations will be transformed to prevent heteroskedasticity.
Depending on the underlying distribution of the data, Student's t-test or Mann-Whitney U will be used to compare individual biomarker expression values, using Bonferroni correction for multiple comparisons.
Immunophenotyping will be analyzed using log-transformed cell counts and comparisons of defined populations between groups, with statistical significance corrected for multiple comparisons.
|
Up to 42 days
|
|
Differences in percentages of immune cell populations
時間枠:Up to 42 days
|
Will be compared between interventions using a repeated measures analysis of variance and between obese and normal body mass index groups.
Immune cell population analyses will be visualized using clustering and t-stochastic neighbor embedding plots.
|
Up to 42 days
|
協力者と研究者
捜査官
- 主任研究者:Holli Loomans-Kropp, PhD, MPH、Ohio State University Comprehensive Cancer Center
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- OSU-25053 (その他の識別子:Ohio State University Comprehensive Cancer Center)
- NCI-2026-01822 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
結腸直腸癌の臨床試験
-
Taichung Veterans General Hospital完了心毒性 | 非小細胞肺癌(MeSH用語:Carcinoma, Non-Small-Cell Lung) | 薬物関連の副作用および有害反応(MeSH用語) | EGFRチロシンキナーゼ阻害剤台湾
-
Fondazione del Piemonte per l'Oncologia募集乳がん | 卵巣がん | 結腸直腸がん | 黒色腫 (皮膚がん) | 非小細胞肺癌(MeSH用語:Carcinoma, Non-Small-Cell Lung)イタリア
アンケート管理の臨床試験
-
Fondazione Poliambulanza Istituto Ospedalieroわからない
-
Fondation Santé des Étudiants de Franceまだ募集していません思春期の行動 | メンタルヘルスの問題
-
Assistance Publique - Hôpitaux de Paris完了
-
Centre Georges Francois Leclerc積極的、募集していないステージ IV の非小細胞気管支肺癌であり、現在のフランスの推奨に従って第一選択治療の恩恵を受けるフランス
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridgeわからない筋骨格疾患 | 筋骨格系損傷
-
Centre Hospitalier Universitaire de Nīmes完了
-
Assistance Publique - Hôpitaux de Parisまだ募集していません